Approach to desensitization in aspirin-exacerbated respiratory disease.

INSTRUCTIONS Credit can now be obtained, free for a limited time, by reading the review article in this issue and completing all activity components. Please note the instructions listed below: Review the target audience, learning objectives and all disclosures. Complete the pre-test online at http://www.annallergy.org (click on the CME heading). Follow the online instructions to read the full version of the article, including the clinical vignette; reflect on all content as to how it may be applicable to your practice. Complete the post-test/evaluation and claim credit earned; at this time, you will have earned up to 1.0 AMA PRA Category 1 CreditTM. Please note that the minimum passing score on the post-test is 70%. Approximately 4-6weeks later youwill receive an online assessment regarding your application of this article to your practice. Once you have completed this assessment, you will be eligible to receive MOC Part II credit from the American Board of Allergy and Immunology. Release Date: January 1, 2014 Expiration Date: December 31, 2015 Estimated Time to Complete: 60 minutes Target Audience: Physicians involved in providing patient care in the field of allergy/asthma/immunology Learning Objectives: At the conclusion of this activity, participants should be able to: Discuss the common clinical findings in aspirin exacerbated respiratory disease Describe a systematic approach to evaluating and treating patients with suspected aspirin exacerbated respiratory disease Accreditation: The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation: The American College of Allergy, Asthma & Immunology (ACAAI) designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Planning Committee Members: Andrew A. White, MD (Author) Michael S. Tankersley, MD (CME Series Editor) Gailen D. Marshall, Jr, MD, PhD (Editor-in-Chief) Disclosure of Relevant Financial Relationships: D.R. Scott, A.A. White, M.S. Tankersley, and G.D. Marshall have no relevant financial relationships to disclose. Reviewers and Education/ Editorial staff have no relevant financial relationships to disclose. The off-label/investigative use of montelukast for aspirin exacerbated respiratory disease is discussed (AERD). Recognition of Commercial Support: This activity has not received external commercial support. Copyright Statement: 2014-2016 ACAAI. All rights reserved. CME Inquiries: Contact the American College of Allergy, Asthma & Immunology at [email protected] or 847-427-1200.